{"id":21193,"date":"2015-09-02T18:05:17","date_gmt":"2015-09-02T16:05:17","guid":{"rendered":"http:\/\/www.fedaiisf.it\/?p=21193"},"modified":"2015-09-12T10:44:05","modified_gmt":"2015-09-12T08:44:05","slug":"le-lobby-farmaceutiche-godono-di-ottima-salute","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/le-lobby-farmaceutiche-godono-di-ottima-salute\/","title":{"rendered":"Pharmaceutical lobbies are in excellent health"},"content":{"rendered":"<p class=\"byline\"><em>Investments on the rise, preferential treatment and deals behind closed doors. A report unmasks the dynamics and relationships between interest groups of the pharmaceutical industry with the European political elite.<\/em><\/p>\n<p class=\"byline\"><a href=\"http:\/\/www.vita.it\/it\/article\/2015\/09\/02\/le-lobby-farmaceutiche-godono-di-ottima-salute\/136353\/\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Martino Pillitteri \u2013 02\/09\/2015 \u2013 <span style=\"text-decoration: underline;\">LIFE<\/span><\/span><\/a><\/p>\n<p class=\"byline\">The recipe that pharmaceutical industry lobbies prescribe to safeguard the financial health of their customers is about 15 times more expensive than that of civil society actors working for public health. But above all it guarantees <strong>privileged access to the decision-making process<\/strong> such as participation in counseling groups and meetings <strong>with the decision makers of the European institutions<\/strong>. As if to say: while the common patient waits his turn in the emergency room, the lobbies go directly to the operating room and are operated on by the head physician.<\/p>\n<div class=\"lf-type2-1 lf-cal-a lf-size1 lf-container lf-block\" data-main-eref=\"photo:8f41c457-e5e0-48da-aee1-42f7b90486a8\">\n<div class=\"lf-inner\">\n<div class=\"lf-child lf-child-2\">\n<div class=\"lf-col1 lf-size1 lf-text lf-block\">\n<div class=\"lf-inner\">\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"http:\/\/i.static.vita.it\/blobs\/variants\/8\/f\/4\/1\/8f41c457-e5e0-48da-aee1-42f7b90486a8_medium.jpg\" alt=\"Lobby 1\" width=\"470\" height=\"233\" \/>An example? There <span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"http:\/\/www.efpia.eu\/\" target=\"_blank\" rel=\"noopener\">EFPIA extension<\/a><\/span> (European Federation of Pharmaceutical Industries and Associations) took home more than 50 meetings with the Juncker Commission during the first four and a half months of its mandate. The study reveals<strong><a href=\"http:\/\/corporateeurope.org\/pressreleases\/2015\/09\/big-money-and-close-ties-behind-big-pharmas-brussels-lobby-efforts-new-study\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">Big money and close ties behind Big Pharma&#039;s Brussels lobby efforts<\/span><\/a>\u201d<\/strong> (Lots of money and close ties, the lobbying efforts of the pharmaceutical industry in Brussels) edited and published by <span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"http:\/\/corporateeurope.org\/\" target=\"_blank\" rel=\"noopener\">Corporate Europe Observatory<\/a><\/span>, a non-profit organization whose mission is to expose the influence of lobbies on the European establishment that counts.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"lf-col1 lf-size1 lf-text lf-block\">\n<div class=\"lf-inner\">\n<p>The influence of the pharmaceutical lobby is capable of blurring the line that separates the legislator from those directly involved. &quot;This almost cooperative relationship,&quot; he says<strong> Yannis Natsis<\/strong> from the <a href=\"http:\/\/tacd.org\/\" target=\"_blank\" rel=\"noopener\">TransAtlantic Consumer Dialogue<\/a>, &quot;emphasizes the work of the independent monitors they carry out on new drugs and their cost&quot;. Translated into practice, the pharmaceutical industry, through the intermediation of lobbies, is essentially trying to <strong>make the drug development path simpler and shorter<\/strong>, or moving from clinical trials to product approval by the competent bodies by cutting the &quot;<strong>regulatory barriers<\/strong>\u201d in a way that suits your business model. <strong><a href=\"http:\/\/corporateeurope.org\/sites\/default\/files\/20150828_bigpharma_web.pdf\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #0000ff;\">According to the study<\/span><\/a>, this dynamic threatens the public interest on issues of access to medicines, drug costs and safety,<\/strong> just to name a few.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignright\" src=\"http:\/\/i.static.vita.it\/blobs\/variants\/2\/e\/8\/0\/2e8051b9-f1fe-4009-af66-8a2986c02041_medium.jpg\" alt=\"Lobby 2\" width=\"476\" height=\"452\" \/>In order to achieve its goals, large pharmaceutical companies <strong>use sophisticated methods of communication and public relations<\/strong>. One example is language that equates the profit-making goals of private companies with public health benefits. This happens through <strong>the ubiquitous use of terms and slogans such as \u201cInnovation\u201d<\/strong>, &#8220;<strong>Research Based on Industry Research<\/strong>\u201d (although most of the research takes place in taxpayer-funded universities), and \u201c<strong>Intellectual Property Rights<\/strong>\u201c, which are not actually rights, but rather, monopoly privileges granted by governments that allow prices to rise.<\/p>\n<p><strong>Behind the term \u201cInnovation\u201d<\/strong>, the study specifies, hides any new drug on the market that has no additional therapeutic value compared to drugs already on the market. Thus &quot;innovation&quot; comes to mean the sale of new drugs, not the discovery and production of new treatments.<\/p>\n<p><span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"http:\/\/corporateeurope.org\/sites\/default\/files\/20150827_bigpharma_web.pdf\" target=\"_blank\" rel=\"noopener\">Policy prescriptions. the firepower of the EU pharmaceutical lobby and implications for public health<\/a><\/span><\/p>\n<p><strong>Related news<\/strong>: <span style=\"color: #0000ff;\"><a style=\"color: #0000ff;\" href=\"http:\/\/www.fedaiisf.it\/en\/lobby-italia-nel-fondo-classifica-della-trasparenza-non-ce-legge-che-le-regoli\/\" target=\"_blank\">Lobby, Italy in the transparency classification fund: &quot;There is no law that regulates them&quot;<\/a><\/span><\/p>\n<p><a href=\"http:\/\/www.fedaiisf.it\/en\/lobby-aziende-influenzano-decisioni-europee\/\" target=\"_blank\">\u00a0<span style=\"color: #0000ff;\">Lobby: here are the companies that influence European decisions<\/span><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignleft\" src=\"http:\/\/i.static.vita.it\/blobs\/variants\/d\/0\/1\/d\/d01d7fff-e33c-493b-bf3c-675b752a5e5f_large.jpg\" alt=\"Lobby 3\" width=\"650\" height=\"446\" \/><\/p>\n<\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Investimenti in ascesa, trattamenti privilegiati e affari a porte chiuse. Un report smaschera le dinamiche e i rapporti tra i gruppi di interessi dell&#8217;industria farmaceutica con l&#8217;elite politica europea. Martino Pillitteri &#8211; 02\/09\/2015 &#8211; VITA La ricetta che le lobby dell\u2019industria farmaceutica prescrive per salvaguardare la salute delle finanze dei propri clienti \u00e8 circa 15 &hellip;<\/p>","protected":false},"author":4,"featured_media":21196,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[47],"class_list":["post-21193","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-primo-piano","tag-big-pharma"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/21193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=21193"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/21193\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/21196"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=21193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=21193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=21193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}